|Adjunct professor, Department of Medical Microbiology, University of Manitoba
Director, R & D, Cangene Corporation, Manitoba
Degrees: B.Sc.(Honors) Biochem (U of Guelph, 1991); Ph.D.Cardiovascular Institute (U of Manitoba, 1997), Post-Doctoral Fellow, Vascular Medicine (U of Western Ontario, 1999)
Mailing Address: Cangene Corporation, 155 Innovation Drive, Winnipeg, Manitoba, Canada R3T 5Y3
Tel: (204) 275-4034 Fax: (204) 275-4005
My research interests focus on improving our understanding of the host response to bacterial infections that encompasses both the innate and adaptive immune response with the end goal of developing effective therapeutics for infectious disease. To delineate the innate immune response, cellular biology will be used to map the complex network of humoral and cellular mechanisms in order to limit pathogens. Research to optimize therapeutics for infectious disease through analysis of the host's adaptive immune response will focus on the pathogen-specific epitopes that correlate with neutralizing potency.
As Director in R&D at Cangene Corp., my research focus includes biotherapeutics for infectious disease and biodefense applications. My role in R&D has been intrinsic to the programs for licensure of antibody based therapeutics for chicken pox, Hepatitis B, Anthrax and Botulism and several biodefense contracts through BARDA/HHS as well as CRTI.
For a list of Dr. Saward's PubMed articles, please click here
- Yau L , Molnar P , Moon MC , Buhay S , Werner JP , Molnar K , Saward L , Del Rizzo D , Zahradka P . (2008) meta-Iodobenzylguanidine, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents neointimal hyperplasia. J. Pharmacol. Exp. Ther. 326(3):717-24.
- Rocnik E, Saward L , Pickering JG.(2001) HSP47 expression by smooth muscle cells is increased during arterial development and lesion formation and is inhibited by fibrillar collagen. Arterioscler Thromb Vasc Biol. 21(1):40-6.
- Wilson DP, Saward L , Zahradka P, Cheung PK (1999) Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res. 42(3):761-72.
- Zahradka P, Yau L, Lalonde C, Buckho J, Thomas S, Werner J, Nguyen M, Saward L (1998) Modulation of the vascular smooth muscle angiotensin subtype 2 (AT2) receptor by angiotensin II. Biochem Biophys Res Comm. 252(2):476-480.
- Shao Q, Saward L , Zahradka P & Dhalla N (1998) Ca2+ mobilization in adult rat cardiomyocytes by angiotensin type 1 and 2 receptors. Biochem Pharmacol. 55(9):1413-1418.
- Zahradka P, Wilson D, Saward L , Yau L & Cheung PK (1998) Cellular physiology of angiotensin II receptors in vascular smooth muscle cells. In Angiotensin II Receptor Blockade: Physiological and Clinical Implications. ( Dhalla , N.S. , Zahradka, P., Dixon , I.M.C., Beamish, R.E. eds.) Boston : Kluwer Academic Publishers.
- Saward L & Zahradka P (1997) Angiotensin II activates phosphatidylinositol-3 kinase in vascular smooth muscle cells. Circ Res. 81(2):249-257.
- Saward L & Zahradka P (1997) Coronary artery smooth muscle in culture: Migration of heterogeneous cell populations from vessel wall. Mol Cell Biochem. 176(1-2):53-59.
- Saward L & Zahradka P (1996) Insulin is required for angiotensin II-mediated hypertrophy of smooth muscle cells. Mol Cell Endocrinol. 122(1): 93-100
- Saward L & Zahradka P (1996) The angiotensin type 2 receptor mediates RNA synthesis in A10 smooth muscle cells. J Mol Cell Cardiol. 28(3): 499-506.